12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Company News  |  Deals

Ascendis, United Therapeutics deal

United Therapeutics received exclusive rights to use Ascendis' TransCon technology in prostacyclin-related products to treat pulmonary arterial hypertension (PAH). United Therapeutics plans to develop a self-injectable version of treprostinil for PAH. Ascendis and United will collaborate on...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >